文献速递甲状腺与浅表介入US

症状性良性甲状腺结节射频消融联合或不联合硬化治疗早期完全消退的预测因素:一项回顾性研究

Predictors of early complete nodule shrinkage in symptomatic benign thyroid nodules treated with radiofrequency ablation with or without sclerotherapy: a retrospective study.
PubMed 文献 · Eur Radiol · 2025-06-18

回顾性纳入118例接受射频消融的症状性良性甲状腺结节患者,平均随访50.5个月,2年内完全消退率为27%(32/118)。初始结节体积较小、无后方回声增强、结节周边血流减少是2年内完全消退的独立预测因素,预测列线图的AUC为0.9655。在接受聚桂醇硬化治疗的患者中,初始结节体积较小和聚桂醇用量减少是独立预测因素。

要点

  • 2年内完全消退率为27%(32/118),初始结节体积较小、无后方回声增强、周边血流减少提示更易早期完全消退。
  • 预测列线图AUC为0.9655,可用于评估早期完全消退以辅助个体化随访。
  • 接受聚桂醇硬化治疗者中,初始结节体积较小和聚桂醇用量减少是独立预测因素。

核心结论

  • 射频消融治疗症状性甲状腺结节有效,预测因素和列线图可用于评估早期完全消退,有助于为患者制定个体化随访方案。

研究设计与样本

  • 回顾性研究,纳入118例接受射频消融联合或不联合硬化治疗的症状性良性甲状腺结节患者,平均随访50.5个月,按2年内结节是否完全消退分组,采用Logistic回归分析独立预后因素并构建预测列线图。

关键影像表现/征象

  • 超声示无后方回声增强是2年内完全消退的独立预测因素(OR 10.771;95%CI 1.521-76.27;p=0.017)。
  • 超声示结节周边血流减少是2年内完全消退的独立预测因素(OR 8.912;95%CI 2.909-27.303;p<0.001)。

诊断标准与关键数值

  • 初始结节体积较小预测2年内完全消退(OR 2.471;95%CI 1.516-4.027;p<0.001)。
  • 无后方回声增强预测2年内完全消退(OR 10.771;95%CI 1.521-76.27;p=0.017)。
  • 结节周边血流减少预测2年内完全消退(OR 8.912;95%CI 2.909-27.303;p<0.001)。
  • 预测列线图评估2年内完全消退的AUC为0.9655。
  • 接受聚桂醇硬化治疗者中,初始结节体积较小和聚桂醇用量减少是独立预测因素。

临床应用与阅片要点

  • 阅片时可关注初始结节体积、后方回声增强及周边血流,用于评估2年内完全消退的可能性。
  • 作者建议使用预测因素和列线图评估早期消退,以辅助个体化随访。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To identify factors influencing the early complete shrinkage of symptomatic benign thyroid nodules following radiofrequency ablation (RFA) with or without sclerotherapy and to predict complete nodule resolution within 2 years, thereby alleviating concerns regarding long-term follow-up outcomes.

MATERIALS AND METHODS: Patients with symptomatic benign thyroid nodules who underwent RFA were retrospectively enrolled. The patients were grouped according to whether their nodules had completely shrunk within 2 years. Logistic regression analyses were conducted to identify independent prognostic factors associated with early complete shrinkage. These factors were subsequently integrated into predictive nomograms.

RESULTS: A total of 118 patients were included with a mean follow-up of 50.5 months. The complete nodule shrinkage rate at 2 years was 27% (32/118). Independent predictors for complete nodule shrinkage within 2 years included a smaller initial nodule volume (odds ratio (OR), 2.471; 95% confidence interval (CI), 1.516-4.027; p < 0.001), absence of posterior echogenicity enhancement (OR, 10.771; 95% CI, 1.521-76.27; p = 0.017), and reduced perinodular vascularity (OR, 8.912; 95% CI, 2.909-27.303; p < 0.001). The predictive nomogram demonstrated a high predictive value with an area under the curve of 0.9655. Furthermore, in patients receiving lauromacrogol sclerotherapy, a smaller initial nodule volume and reduced use of lauromacrogol were independent predictors.

CONCLUSION: This study demonstrated the efficacy of RFA in treating symptomatic thyroid nodules and suggested the use of predictive factors and a nomogram to assess early shrinkage, which would facilitate personalized follow-up for patients.

KEY POINTS: Question What factors predict early complete shrinkage of symptomatic benign thyroid nodules after radiofrequency ablation. Findings A smaller initial volume, the absence of posterior echogenic enhancement, and reduced perinodular vascularity on ultrasound were predictive of complete shrinkage within 2 years. Clinical relevance This study enabled physicians to better address patients' concerns regarding the pace of nodule shrinkage and the persistence of nodules even after extended periods. This understanding helps alleviate anxiety for both us and patients when determining the follow-up endpoint.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Qiu Y, Lin T, Feng M, et al. Predictors of early complete nodule shrinkage in symptomatic benign thyroid nodules treated with radiofrequency ablation with or without sclerotherapy: a retrospective study. Eur Radiol. 2025. PMID: 40531318. doi:10.1007/s00330-025-11767-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。